Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma
89 percent of 509 patients would have been ineligible for MajesTEC-1 trial; estimated median PFS was 5.8 months
Nocturnal Hypertension Control Improved With Bedtime Antihypertensive Dosing
Better control of nocturnal blood pressure and improved circadian rhythm seen with bedtime versus daytime dosing
Anticholinergics Tied to Physical Performance Decline in Older Adults
Authors say findings support guidance to avoid these medications when possible
Thousands Laid off From NIH, FDA and CDC After Supreme Court Decision
Court Allows West Virginia to Restrict Abortion Pill Mifepristone
WHO, UNICEF Say More Than 14 Million Infants Worldwide Remain Unvaccinated
However, improvements seen in vaccination rates for diphtheria-tetanus-pertussis, measles, HPV
Approved-Label Populations for New Drugs Broader Than Trial Populations
Inconsistency seen most often in terms of patient fitness, with variance in almost all approved indications
Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment
Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction
Cell Therapy MDR-101 Produces Functional Immune Tolerance in Kidney Transplant Recipients
Fifteen of 20 HLA-matched living donor recipients achieved the primary end point of being immunosuppression-free for more than two years
ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use
For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss
